Recommendations for economic evaluations of cell and gene therapies: a systematic literature review with critical appraisal

被引:5
作者
Toumi, Mondher [1 ,10 ]
Dabbous, Omar [2 ]
Aballea, Samuel [3 ]
Drummond, Michael F. [4 ]
von der Schulenburg, Johann-Matthias Graf [5 ]
Malone, Daniel C. [6 ]
Neumann, Peter J. [7 ]
Sullivan, Sean D. [8 ]
Tunis, Sean [9 ]
机构
[1] Aix Marseille Univ, Publ Hlth Dept, Lab Sante Publ, Marseille, France
[2] Novartis Gene Therapies Inc, Global Genecon & Outcomes Res, Bannockburn, IL USA
[3] Creativ Ceut, Paris, France
[4] Univ York, Ctr Hlth Econ, York, England
[5] Leibniz Univ Hannover, Inst Risk & Insurance, Hannover, Germany
[6] Univ Utah, Dept Pharmacotherapy, Salt Lake City, UT USA
[7] Tufts Med Ctr, Inst Clin Res & Hlth Policy Studies, Ctr Evaluat Value & Risk Hlth, Boston, MA USA
[8] Univ Washington, CHOICE Inst, Seattle, WA USA
[9] Rubix Hlth, Baltimore, MD USA
[10] Aix Marseille Univ, Publ Hlth Dept, Lab Sante Publ, 27 Blvd Jean Moulin, F-13385 Marseille, France
关键词
Cost-effectiveness analysis; economic evaluation; gene therapy; health technology assessments; health-related quality of life; onasemnogene abeparvovec; spinal muscular atrophy; systematic literature review; COST-EFFECTIVENESS ANALYSIS; HEALTH TECHNOLOGY-ASSESSMENT; REGENERATIVE MEDICINES; VORETIGENE NEPARVOVEC; ADULT PATIENTS; CHALLENGES; TISAGENLECLEUCEL; LYMPHOMA; PRODUCTS;
D O I
10.1080/14737167.2023.2197214
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Objective: No consensus exists on the ideal methodology to evaluate the economic impact and value of new, potentially curative gene therapies. We aimed to identify and describe published methodologic recommendations for the economic evaluation of gene therapies and assess whether these recommendations have been applied in published evaluations.Methods: This study was conducted in three stages: a systematic literature review of methodologic recommendations for economic evaluation of gene therapies; an assessment of the appropriateness of recommendations; and a review to assess the degree to which the recommendations were applied in published evaluations.Results: A total of 2,888 references were screened, 83 articles were reviewed to assess eligibility, and 20 papers were included. Fifty recommendations were identified, and 21 reached consensus thresholds. Most evaluations were based on naive treatment comparisons and did not apply consensus recommendations. Innovative payment mechanisms for gene therapies were rarely considered. The only widely applied recommendations related to modeling choices and methods.Conclusions: Methodological recommendations for economic evaluations of gene therapies are generally not being followed. Assessing the applicability and impact of the recommendations from this study may facilitate the implementation of consensus recommendations in future evaluations.
引用
收藏
页码:483 / 497
页数:15
相关论文
共 79 条
  • [31] Gottlieb S., 2019, Statement from FDA Commissioner Scott Gottlieb, M.D. On the agencys new efforts to strengthen regulation of dietary supplements by modernizing and reforming FDAs oversight
  • [32] Potential lifetime quality of life benefits of choroideremia gene therapy: projections from a clinically informed decision model
    Halioua-Haubold, Celine-Lea L.
    Jolly, Jasleen K.
    Smith, James A.
    Pinedo-Villanueva, Rafael
    Brindley, David A.
    MacLaren, Robert E.
    [J]. EYE, 2019, 33 (08) : 1215 - 1223
  • [33] Gene therapy: evidence, value and affordability in the US health care system
    Hampson, Grace
    Towse, Adrian
    Pearson, Steven D.
    Dreitlein, William B.
    Henshall, Chris
    [J]. JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2018, 7 (01) : 15 - 28
  • [34] The assessment and appraisal of regenerative medicines and cell therapy products: an exploration of methods for review, economic evaluation and appraisal
    Hettle, Robert
    Corbett, Mark
    Hinde, Sebastian
    Hodgson, Robert
    Jones-Diette, Julie
    Woolacott, Nerys
    Palmer, Stephen
    [J]. HEALTH TECHNOLOGY ASSESSMENT, 2017, 21 (07) : 1 - +
  • [35] Challenges and advantages of cell therapy manufacturing under Good Manufacturing Practices within the hospital setting
    Iancu, Emanuela M.
    Kandalaft, Lana E.
    [J]. CURRENT OPINION IN BIOTECHNOLOGY, 2020, 65 : 233 - 241
  • [36] Comparison of regulatory pathways for the approval of advanced therapies in the European Union and the United States
    Iglesias-Lopez, Carolina
    Obach, Merce
    Vallano, Antonio
    Agusti, Antonia
    [J]. CYTOTHERAPY, 2021, 23 (03) : 261 - 274
  • [37] Predictors of Caregiver Burden among Mothers of Children with Chronic Conditions
    Javalkar, Karina
    Rak, Eniko
    Phillips, Alexandra
    Haberman, Cara
    Ferris, Maria
    Van Tilburg, Miranda
    [J]. CHILDREN-BASEL, 2017, 4 (05):
  • [38] Cost-effectiveness of Voretigene Neparvovec-rzyl vs Standard Care for RPE65-Mediated Inherited Retinal Disease
    Johnson, Scott
    Buessing, Marric
    O'Connell, Thomas
    Pitluck, Sarah
    Ciulla, Thomas A.
    [J]. JAMA OPHTHALMOLOGY, 2019, 137 (10) : 1115 - 1123
  • [39] Advanced therapy medicinal products and health technology assessment principles and practices for value-based and sustainable healthcare
    Jonsson, Bengt
    Hampson, Grace
    Michaels, Jonathan
    Towse, Adrian
    von der Schulenburg, J. -Matthias Graf
    Wong, Olivier
    [J]. EUROPEAN JOURNAL OF HEALTH ECONOMICS, 2019, 20 (03) : 427 - 438
  • [40] Jorgensen Jesper, 2018, J Mark Access Health Policy, V6, P1500419, DOI 10.1080/20016689.2018.1500419